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Abstract
N,N-diethyl-m-toluamide (DEET) has been registered for commercial use as an insect repellent for over five decades,
and is used widely across the world. Concerns over the safety of DEET first emerged during the 1980s after reports
of encephalopathy following DEET exposure, particularly in children. However, the role of DEET in either the illness
or deaths was and remains purely speculative. In response to these cases a number of reviews and investigations of
DEET safety were carried out. Here we examine the methods used and information available to determine the
safety of DEET in humans. Animal testing, observational studies and intervention trials have found no evidence of
severe adverse events associated with recommended DEET use. Minor adverse effects noted in animal trials were
associated with very large doses and were not replicated between different test species. The safety surveillance
from extensive humans use reveals no association with severe adverse events. This review compares the toxicity
assessment using three different models to define the risk assessment and safety threshold for DEET use in humans
and discusses the clinical consequences of the thresholds derived from the models.
The theoretical risks associated with wearing an insect repellent should be weighed against the reduction or
prevention of the risk of fatal or debilitating diseases including malaria, dengue, yellow fever and filariasis. With over
48 million European residents travelling to regions where vector borne diseases are a threat in 2009, restricting the
concentration of DEET containing repellents to 15% or less, as modelled in the 2010 EU directive, is likely to result
in extensive sub-therapeutic activity where repellents are infrequently applied. Future European travellers, as a
consequence of inadequate personal protection, could potentially be at increased risk of vector borne diseases. Risk
assessments of repellents should take these factors into account when setting safe limits.
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Introduction
N,N-diethyl-m-toluamide (DEET) is amongst the most
effective and widely used of insect repellents [1]. DEET
was one of the first synthetic repellents, initially developed
by the United States Department of Agriculture and then
used by the military. It was registered for use by the general
public in 1957, and remains the most widely used repellent
with an estimated 30% of the US population using insect
repellent in 2000 [2]. In 2011, a sample survey for the EPA,
showed that US consumers bought insect repellent on
average 2.87 times per year, and 3.49 times if there were
children in the family [3]. Given the greater awareness of
vector borne diseases such as West Nile virus, tick-borne
encephalitis and Lyme disease, insect repellent use is likely
to increase, and sales reports show that sales of insect re-
pellents increased 28% between 2001 and 2003 [4]. There
are now a range of synthetic and naturally derived repellent
compounds, and of these, Icaridin and PMD have been
shown to provide effective protection, however, due to its
long history DEET still has the strongest body of evidence
for efficacy [5]. Another synthetic repellent, IR3535 has
shown reduced efficacy against Anopheles mosquitoes and
as such is not recommended for travellers to endemic areas
[5]. In testing of new actives ingredients, 20% DEET is the
gold standard for comparison [6] and shows efficacy against
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a wide variety of blood-feeding organisms: from mosquitoes
and black flies to ticks, mites and even land leeches [7].
Concerns over the safety of DEET first emerged in the
1980s after reports of encephalopathy following DEET
exposure, particularly in children [8,9]. Although the role of
DEET in these cases was purely speculative, they prompted
a number of investigations and a number of reviews of the
safety of DEET.
The process of undertaking a comprehensive safety
risk assessment of a chemical requires a four stage re-
view [10]. The first stage is hazard identification, which
identifies the capacity of the chemical to generate ad-
verse effects in humans. The second is a dose–response
test to establish a relationship between dose and the
incidence of adverse events. The third includes toxicity
assessment data from animal or human exposure to define
a final safe exposure limit in humans (Figure 1). Much of
the data used to assess the safety of DEET relies on animal
studies, with only a single observational trial of DEET use
in pregnancy so far carried out on humans. The final stage
is a risk assessment that combines the safe exposure limits
with likely levels and routes of exposure.
Toxicity studies of DEET in animals
Animal toxicity testing provides basic data where human
exposure information is inadequate or unavailable. Most
tests only collect information on obvious toxicity effects
such as changes in body weight, without defining the
Figure 1 The processes involved in creating a safe exposure assessment of any chemical.
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mechanisms of toxicity. The United States Environmental
Protection Agency (USEPA) carried out a series of experi-
ments in 1998 as part of a DEET re-registration process
[11]. The majority of studies revealed minor effects of
DEET and different NOEL, depending on the exposure
route (Table 1). The experiments of most interest involve
dermal exposures to DEET, including a 90-day dermal tox-
icity study in rats using exposures up to 1000 mg/kg body
weight/day. At the greatest exposure male rats were ob-
served to develop renal lesions and a decreased body
weight, and both sexes showed increased liver weights.
As renal lesions were observed in all males at every expos-
ure level, the study was unable to establish a no observed
effect level (NOEL). Detailed investigations revealed that
the renal lesions were unique to male rats and not relevant
to human health [11]. A similar study using micropigs,
found no changes in mortality, body weight, blood bio-
chemistry, gross pathology or organ weights due to DEET
exposure up to 1000 mg per kg body weight per day [11].
Studies and case reports of DEET safety in humans
Studies in humans have clear advantages as they avoid
the errors when extrapolating results from animal studies.
In humans, secondary risk factors such as smoking and
diet can also be considered. Testing involving animals
will largely be drawn from homogenous populations with
similar susceptibility to the chemical being tested, whereas
human populations will mostly contain a wide range of in-
dividuals with varying susceptibility. Observational studies
and case reports form the basis of most human toxico-
logical studies. Case reports, although highly subjective and
sometimes anecdotal, can be useful in identifying rare asso-
ciated effects such as unique reactions or association with
rare diseases. Observational studies, not easily done, do not
allow for any control of assignment of study subjects to
either group or the levels of exposure and controlling
for confounding factors. Randomised trials using human
subjects provide the most rigorous data on safety, but
for ethical and safety reasons these trials are rare in
toxicological investigations.
Although no human studies have been carried out spe-
cifically to assess the safety of DEET, a randomised trial
of DEET used to prevent malaria transmission amongst
pregnant women in Thailand did assess health outcomes
in participants [12]. The women were all past their first
trimester and when recruited to the trial were monitored
for the duration of the pregnancy at weekly ante-natal
visits. Their babies were then monitored monthly until six
months old and then every three months until one year.
No significant differences were found between the DEET
treatment group and control group in weight, height, head
and arm circumferences, and neurologic performance in
Table 1 Results of toxicity testing of DEET on animals reported to the USEPA [11]
Test type Animal Outcome
Acute oral toxicity Rat Oral LD50 = 2170–3664 mg/kg
Toxicity category III: Slightly toxic and slightly irritating
Acute dermal toxicity Rabbit Dermal LD50 = 4280 mg/kg
Toxicity category III: Slightly toxic and slightly irritating
Acute inhalation toxicity Rat Inhalation LD50 = 5.95 mg/kg
Toxicity category IV: Practically non-toxic and not an irritant
Subchronic (90 day) oral toxicity Rat Renal effects found in exposed male rats of two of three
strains tested so no NOEL established.
Subchronic (90 day) oral toxicity Hamster NOEL: 61 mg/kg/day
LEL: 305 mg/kg/day
Subchronic (90 day) dermal toxicity Rat Renal lesions in all male rats treated so no NOEL established
Subchronic (90 day) dermal toxicity Micropigs NOEL: 1000 mg/kg/day
Chronic (2 year) toxicity Rats and dogs NOEL: 100 mg/kg/day
LEL: 400 mg/kg/day
No carcinogenic effects
Chronic (78 weeks) toxicity Mice NOEL: 500 mg/kg/day
LEL: 1000 mg/kg/day
No carcinogenic effects
Reproductive toxicity Rats NOEL: 250 mg/kg/day (highest dose tested)
Developmental and maternal toxicity Rats NOEL: 250 mg/kg/day
LEL: 750 mg/kg/day
Developmental toxicity Rabbits NOEL: 325 mg/kg/day (Highest dose tested)
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newborns. Similarly, infants followed to one year showed
no significant difference in developmental delay, death,
weight, height, head circumference and arm circumfer-
ence between those whose mothers had used DEET and
non-users. Neither were there any differences in the oc-
currences of neurological or gastrointestinal effects in the
women. Skin warming, a heating sensation on the skin,
was significantly more common in the DEETgroup. DEET
was not detected in urine, however, it was detected in the
cord blood from four (8%) of the women indicating that
DEET is able to cross the placenta. The ability of DEET to
cross the placenta is confirmed in a survey of pesticides in
cord blood amongst mothers in New Jersey [13]. DEET
was detectable in the blood and cord blood of all women
analysed, although no significant effects on birth weight,
head circumference or birth length were found, but a bor-
derline association between higher DEET levels in the
cord blood and higher abdominal circumference was
noted. At present such trials are rare and limited, so there
is no data for the safety of DEET in the first trimester, on
the effects of ante-natal DEET exposure beyond one year
follow up.
During the mid-1980s there were six reported cases of
encephalopathy following exposure to DEET, all in girls
aged 1–8 years which resulted in three deaths [8]. How-
ever, it is unclear whether exposure to DEET was the real
cause of the seizures or deaths. The first case involved a 3
and a half year old girl who developed seizures, and it was
reported that for the two weeks prior to the illness DEET
had been applied to her clothes, bedding and skin result-
ing in an estimated exposure of 0.14 ml per kg body
weight per day [14]. One of the fatal cases involved a six
year old girl [15] who had applied DEET ‘extensively’.
However, in this case a history of similar episodes without
DEET exposure led to the hypothesis that the girl may
have had undiagnosed ornithine carbamyl transferase defi-
ciency. In this case medical opinion was that, although
DEET may have precipitated the episode, the cause of
death may have been one of the medicines administered
during her stay in hospital. A further case was of an 8 year
old girl who developed a rash on areas where DEET had
been ‘copiously’ applied in the previous 4 days [16]. She
then suffered seizures before making full recovery. The
authors reporting the case believed that, in contrast to
previous reports, this case was a true hypersensitive reac-
tion to DEET.
Ten years later there had been a further eight cases of
nervous system toxicity following DEET exposure. No
gender bias was found across all fourteen cases, but all but
one involved children under 8 years [17]. The prevalence
of encephalopathy during this age range is higher as is the
use of DEET use and encephalopathy, therefore it is not
surprising to find an apparent association in some cases
[18]. Despite the term ‘DEET-induced encephalopathy’ in
some case reports [19], no link to dose or mechanistic
pathway has been demonstrated between the use of DEET
and the occurrence of encephalopathy. Although DEET
might be causally associated in these cases, often there is a
lack of data on the actual concentrations and exposures
involved. A full analysis of these cases is not intended in
this review, as the subject has been ably covered by other
authors [9,17]. An analysis was made of over 9,000 calls
relating to DEET exposure that were placed to American
Poison Control Centres from 1985–9 [20]. Almost 90%
were treated solely at home and 80% of those referred to
a health centre were discharged after initial examination
suggesting mild or short-lived symptoms. The severity
of symptoms was found to be more closely related to
the type of exposure with inhalation or contact with
eyes causing greater symptoms, than the concentration
of DEET or the age or gender of the patient. A second
review of over 20,000 calls between 1993–7 found con-
sistent results [21].
A DEET Registry was created to collate information on
severe adverse neurological or systemic events associated
with DEET use in a standardised way in order to evaluate
any potential causal relationship [9]. Two hundred and
forty-two cases that had been referred to the DEET Regis-
try between 1995 and 2001 were assessed by qualified
nurses and followed up after one year. It was found that
children were not disproportionately represented amongst
cases. Children made up 41% of DEET cases in this ana-
lysis compared to 65% of any calls to Poisons Centres be-
tween 1983 and 2009 [22]. However, compared to adults
in the analysis, children were more likely to have experi-
enced seizures and 71% of seizure patients were children.
This is not a remarkable finding, however, as seizures are
more common in children than adults [23]. No relation-
ship was evident between DEET concentration and sever-
ity of outcome, but as with the case reports of seizures
described above, estimating actual DEET exposure is diffi-
cult given the variation in self-administered doses.
Even when allowing for a large factor of underreporting,
the incidence of 14 reported cases of DEET-associated en-
cephalopathy since 1957 is small when considered against
the context of an estimated 200 million applications of
DEET worldwide each year [2]. Some individuals can de-
velop allergic responses to DEET, which result in serious
reactions through even small exposures [24]. However, for
adult consumers, and based on these observational stud-
ies, there is no basis in the observational data for concerns
over the safety of DEET.
Risk assessment of DEET
Results from animals need to be extrapolated to be rele-
vant to human health. It is standard practice to take 10%
of NOEL from animal data to account for differences be-
tween animal and human metabolism and then a further
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adjustment to 10% of that dose (100th the original dose),
to create a safe maximum exposure limit [10]. However,
as this approach can lead to a large correction factor, it
is acknowledged that risk assessments resulting in un-
acceptable exposures should be further examined to en-
sure the findings are sensible and that a more refined
assessment is not required [25].
Antwi et al. carried out a risk assessment of DEET [26]
using both the results of USEPA toxicity testing and those
of Schoenig et al. in which DEET was only administered or-
ally [11,27]. To estimate risk to human health NOELs were
set at 200 mg/kg body weight/day for acute exposures,
300 mg/kg body weight/day for subchronic exposures and
100 mg/kg body weight/day for chronic exposures. A sur-
vey of repellent use by men, women and children found
that the dose applied did not vary with age, gender or the
actual DEET concentration [28]. The average dose applied
in a single application was 3.7 g. Antwi et al. then used this
to model the level of DEET exposure associated with the
use of 5%, 25% and 40% DEET repellent products. None of
the estimated exposures were equal or greater than the
NOELs. However, a single 3.7 g application of a 40% DEET
product is above 1% of the NOEL for all age groups and
a single application of 25% is above 1% of the NOEL for
children under 17 years old. The 1% of the NOEL, as
established from animal testing, is recognised as the safe
exposure limit. This therefore means a 40% DEET prod-
uct is qualified as unsafe for human use but is based on
rat experimental data, where animals at higher dose expo-
sures developed non-specific weight loss and male renal
abnormalities.
The USEPA committee, however, considered the effects
observed in rats at 1000 mg per kg body weight per day as
so modest and the dosage so high, that it did not form suf-
ficient grounds for conducting a quantitative risk assess-
ment. They did not ,therefore, define a minimum dose of
DEET for daily use.
The 2010 EU directive, using the same data source as
the USEPA recommends an acceptable exposure level
(AEL) for repeated use of 8.2 mg DEET per kg body
weight per day [29]. This dose is equivalent to a single
application of 3.3 g of a 15% DEET formulation to an adult
weighing 60 kg. The directive has used the standard 1%
correction shown in Figure 1 as well as an 82% correction
for different absorption rates between animals and humans
to achieve this final safety margin. This assessment did not
reference the different outcomes and findings of the
USEPA study.
All three studies have used the same toxicity data to
determine safe exposure levels, but only the USEPA con-
sidered a full risk assessment was not necessary. Based
on the modest effects of DEET shown in the human tox-
icity data, it is questionable as to whether a risk assess-
ment should be done. The decision about whether a
chemical should be given a full risk assessment is an im-
portant step as often chemicals with low toxicity do not
require this assessment. The different conclusions, based
on the same data, demonstrate the difficulties and un-
certainties involved in modelling toxicity.
Synergistic effects of DEET with insecticides
Illnesses reported by service personnel returning from the
Gulf War have been linked to synergistic effects of DEET
used alongside permethrin (an insecticide impregnated
into clothing) and pyridostigmine bromide (a prophylactic
agent against the effects of nerve gas). In toxicity studies
using animals, rats exposed to combinations of DEET and
pyridostigmine bromide had greater than expected mortal-
ity, but lower than expected mortality was observed in rats
exposed to combinations of DEET and permethrin [11].
Pyridostigmine bromide alone has been shown to impair
rat behavioural performance, but combined with DEET
leads to further loss in performance [30]. As an anti-nerve
gas agent, few people would be expected to be exposed to
pyridostigmine bromide. Therefore, it is possible to control
combined exposure in these select group without prohibit-
ing the use of DEET. The combination of DEET and per-
methrin is a more likely combination in use in the general
population with products such as insecticide treated bed
nets and clothing. In vitro and animal experiments show
that DEET is a cholinesterase inhibitor [31], and in com-
bination with permethrin has measurable effects indicating
DNA damage and oxidative stress in rats, and also in-
creases the release of rat brain mitochondrial cytochrome
C and disrupts the blood–brain barrier (BBB) in rats [32].
Further work is required to determine the mechanism
that could lead to adverse effects for human health using
doses and applications that are relevant to DEET use by
travellers.
Implications for disease transmission
The use of repellents as personal bite protection is rec-
ommended to travellers for protection against arthropod
borne diseases in tropical countries. However, mostly
due to concerns over cost rather than long term exposure,
it is not recommended to people living in vector-borne
disease endemic countries. Although there have been rela-
tively few studies that have measured disease outcomes
associated with the use of repellents alone, and those that
have been published have resulted in variable results in
protection, there is evidence that topical repellents can re-
duce vector borne disease transmission including malaria
[33,34] as well as pediculosis, sandfly fever and scrub ty-
phus [35]. The efficacy of repellents, in part, relies on the
efficacy of the active ingredient, the longevity (how long it
lasts) and user compliance. Undoubtedly, DEET is the
most effective and long-lasting providing the concentra-
tion is high enough and it is well-formulated. In laboratory
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testing different concentrations have been shown to pro-
vide different protection times. For example, in one study,
formulations of DEET below 20% provided complete pro-
tection for only 20 minutes, whereas in comparable tests,
those between 20-50% provided complete protection for
3 hours [36]. Bearing in mind the likely effect of sweating
and rubbing off on clothes in hot climates, the level of
DEET on the skin is likely to reduce rapidly in this envir-
onment. In another study, people who exercise after ap-
plying a repellent based soap have been found to have
10-30% less protection from bites compared to those
who had not exercised [37]. Therefore, to achieve high
levels of protection and maintain this over a practical time
period before having to reapply is essential for any repel-
lents to protect against disease transmission in travellers.
The suggested application rate of 8.2 mg DEET per kg body
weight per day, equates to a single application of 2.46 g of a
20% DEET product for an adult. The application volume or
weight of a DEET product, based on the standard applica-
tion used in repellency testing of 1.67 ml/mg/cm2 required
to cover 2 arms would be 5.7 ml/g product (18% surface
area). A 15% concentration product would contain 855 mg
DEET and a 50% product would contain 2850 mg of DEET.
These DEET levels are above the Directives maximum
492 mg per day (for a person weighing 60 kg) and would
not allow repeated application or application to other parts
of the body sufficient to provide long lasting protection
against most vectors of disease. In field testing of 20-35%
DEET formulations, investigators have used up to 6 ml to
protect exposed limbs, usually forearms, lower legs and feet
[38], but sometimes only the lower legs [39,40].
Conclusions
Risk assessments of chemical exposures rely on exposure
and toxicity assessments which both involve a margin of
error. Risk assessments use a conservative estimate of
exposure to describe the lowest safe estimates of toxicity.
To ensure low-risk chemicals are not subjected to lengthy
assessments a tiered approach is normally used [25]. With
DEET assessments, this is the point at which there is a dif-
ference in approach between researchers. The standard
risk assessment takes the toxicity profile in rats, applies a
conversion factor to apply the data to humans and an-
other to establish a safe exposure level. This blind ap-
proach finds normal exposure DEET products above 15%
leads to excessive exposure. In contrast, other researchers
considered the observed adverse effects in rats (reduced
food consumption and decreased weight gain) has no rele-
vance to human risk and therefore do not complete any
further risk assessment.
Biting arthropods transmit an array of vector-borne
pathogens that cause diseases including malaria, dengue,
Lyme disease, filariasis, onchocerciasis and West Nile virus.
These diseases have a significant human health impact and
many have no specific prophylaxis, treatment or vaccines.
Therefore, insect repellents are important in reducing or
preventing these insect borne infections. DEET is the most
effective and widely used insect repellent with an estimated
200 million annual applications worldwide. With over 48
million European residents travelling annually to regions
where vector borne diseases are a threat [41], restricting
the concentration of DEET containing repellents to 15% or
less, as modelled in the 2010 EU directive based on toxicity
estimates from NOELS in animals, is likely to result in
extensive sub-therapeutic activity where repellents are
infrequently applied [5,42]. Comparisons between mar-
keted repellents show that formulation as well as DEET
concentration will greatly effect longevity of protection
[43], therefore, although not yet available, low DEET repel-
lents could eventually provide a long-lasting protection. Fu-
ture European travellers, as a consequence of inadequate
personal protection, are likely to be at increased risk of vec-
tor borne diseases. It is therefore essential that any risk as-
sessment of the toxicity of DEET needs to be balanced by
its benefit in avoiding disease and extensive global data on
the widespread use of DEETand reported human toxicity.
Policy recommendation on DEET use needs to balance
the available toxicity data, and its historical safety record,
against the risks of vector borne diseases. Conventional
risk assessment methodology leads to a recommendation
to reduce the use of higher concentrations of DEET, but
fails to recognise the disease avoiding benefits of DEET. A
pragmatic approach along with future research to describe
toxicity thresholds in humans are the way forward.
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